̽»¨¾«Ñ¡

Jenny Mjösberg

Jenny Mjösberg

Professor
E-postadress: jenny.mjosberg@ki.se
Telefon: +46852482917
Mobiltelefon: +46705472956
µþ±ð²õö°ì²õ²¹»å°ù±ð²õ²õ: Alfred Nobels allé 8, plan 7, 14152 Huddinge
Postadress: H7 Medicin, Huddinge, H7 CIM Mjösberg, 171 77 Stockholm
Del av:

Om mig

  • Jenny Mjösberg är professor i vävnadsimmunologi vid institutionen för medicin, Huddinge sedan 1 juli 2022.

    Hon studerade biomedicinsk kemi vid Högskolan i Kalmar med examen 2003, och disputerade i klinisk immunologi vid Linköpings universitet 2010. Hon gjorde postdoc vid University of Amsterdam, Nederländerna, 2010–2012 och kom därefter till KI, inledningsvis som postdoc. 2014 blev hon ledare för en egen forskargrupp. Åren 2016–2019 var hon även engagerad som föreläsare vid Linköpings universitet på 20 procent.

    Jenny Mjösberg blev docent 2019. Hon har bland annat tilldelats Vetenskapsrådets Consolidator Grant 2019, ERC Starting Grant 2020 och KI:s Consolidator Grant 2022.

Artiklar

  • Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2025;122(6):e2414230122
    Boulouis C; Mouchtaridi E; Muller TR; Mak JYW; Fairlie DP; Bergman P; Michaelsson J; Halfvarson J; Mjosberg J; Buggert M; Sandberg JK
  • Article: GENES AND IMMUNITY. 2025;26(1):70-74
    Strunz B; Momayyezi P; Bilev E; Muvva JR; Chen P; Bister J; Schaffer M; Akber M; Cornillet M; Horowitz A; Malmberg K-J; Rooyackers O; Aleman S; Ljunggren H-G; Bjorkstrom NK; Stralin K; Hammer Q
  • Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2025;55(2):e202451150
    Rodahl IE; Ivarsson MA; Loh L; Mold JE; Westgren M; Friberg D; Mjosberg J; Bjorkstrom NK; Marquardt N; Nixon DF; Michaelsson J
  • Article: SCIENCE IMMUNOLOGY. 2024;9(99):eadn2362
    Kammann T; Cai C; Sekine T; Mouchtaridi E; Boulouis C; Nilsen V; Ballesteros OR; Mueller TR; Gao Y; Raineri EJM; Mily A; Adamo S; Constantz C; Niessl J; Weigel W; Kokkinou E; Stamper C; Marchalot A; Bassett J; Ferreira S; Rodahl I; Wild N; Brownlie D; Tibbitt C; Mak JYW; Fairlie DP; Leeansyah E; Michaelsson J; Marquardt N; Mjosberg J; Jorns C; Buggert M; Sandberg JK
  • Article: JOURNAL OF INFECTIOUS DISEASES. 2024;230(2):e318-e326
    Strunz B; Maucourant C; Mehta A; Wan H; Du L; Sun D; Chen P; Nordlander A; Gao Y; Cornillet M; Bister J; Kvedaraite E; Christ W; Klingstrom J; Geanon D; Parke A; Ekwall-Larson A; Rivino L; MacAry PA; Aleman S; Buggert M; Ljunggren H-G; Pan-Hammarstrom Q; Lund-Johansen F; Stralin K; Bjorkstrom NK
  • Article: PLOS PATHOGENS. 2024;20(7):e1012390
    Garcia M; Garcia AC; Weigel W; Christ W; Lira-Junior R; Wirth L; Tauriainen J; Maleki K; Vanoni G; Vaheri A; Makela S; Mustonen J; Nordgren J; Smed-Sorensen A; Strandin T; Mjosberg J; Klingstrom J
  • Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2024;54(4):e2350660
    Stamper CT; Marchalot A; Tibbitt CA; Weigel W; Jangard M; Theorell J; Mjosberg J
  • Article: NATURE COMMUNICATIONS. 2024;15(1):1752
    Kvedaraite E; Lourda M; Mouratidou N; Duking T; Padhi A; Moll K; Czarnewski P; Sinha I; Xagoraris I; Kokkinou E; Damdimopoulos A; Weigel W; Hartwig O; Santos TE; Soini T; Van Acker A; Rahkonen N; Tullberg MF; Ringqvist E; Buggert M; Jorns C; Lindforss U; Nordenvall C; Stamper CT; Unnersjoe-Jess D; Akber M; Nadisauskaite R; Jansson J; Vandamme N; Sorini C; Grundeken ME; Rolandsdotter H; Rassidakis G; Villablanca EJ; Idestroem M; Eulitz S; Arnell H; Mjoesberg J; Henter J-I; Svensson M
  • Article: NATURE COMMUNICATIONS. 2024;15(1):683
    Dean I; Lee CYC; Tuong ZK; Li Z; Tibbitt CA; Willis C; Gaspal F; Kennedy BC; Matei-Rascu V; Fiancette R; Nordenvall C; Lindforss U; Baker SM; Stockmann C; Sexl V; Hammond SA; Dovedi SJ; Mjoesberg J; Hepworth MR; Carlesso G; Clatworthy MR; Withers DR
  • Article: CELL REPORTS. 2023;42(11):113425
    Tacho-Pinot R; Stamper CT; King JI; Matei-Rascu V; Richardson E; Li Z; Roberts LB; Bassett JW; Melo-Gonzalez F; Fiancette R; Lin I-H; Dent A; Harada Y; Finlay C; Mjosberg J; Withers DR; Hepworth MR
  • Journal article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2023;143(11):s357
    Hoffer E; Zheng W; Beatrice Z; Sortebech D; Agerholm-Nielsen R; Zhang C; Schønfeldt T; Trselic T; Papavasileiou S; Kärner J; Ehrström M; Gahm J; Mjösberg J; Lysell J; Ødum N; Bryceson Y; Brunner P; Gerlach C; Eidsmo L
  • Article: ALLERGY. 2023;78(9):2533-2536
    Björkander S; Maier P; Kere M; Merid SK; Wirth L; Wiegel W; Ekström S; Kull I; Bergström A; Melén E; Mjösberg J; Tibbitt CA
  • Article: IMMUNITY. 2023;56(6):1285-1302.e7
    Zitti B; Hoffer E; Zheng W; Pandey RV; Schlums H; Casoni GP; Fusi I; Nguyen L; Karner J; Kokkinou E; Carrasco A; Gahm J; Ehrstrom M; Happaniemi S; Keita AV; Hedin CRH; Mjosberg J; Eidsmo L; Bryceson YT
  • Article: CELL REPORTS MEDICINE. 2023;4(5):101038
    Kokkinou E; Soini T; Pandey RV; van Acker A; Theorell J; Czarnewski P; Kvedaraite E; Vandamme N; Lourda M; Sorini C; Weigel W; Carrasco A; Tibbitt CA; Schlums H; Lindforss U; Nordenvall C; Ljunggren M; Idestrom M; Svensson M; Henter J-I; Villablanca EJ; Bryceson YT; Rolandsdotter H; Mjosberg J
  • Article: LANCET REGIONAL HEALTH-EUROPE. 2023;28:100608
    Yu Z; Ekstrom S; Bellander T; Ljungman P; Pershagen G; Eneroth K; Kull I; Bergstrom A; Georgelis A; Stafoggia M; Gruzieva O; Melen E
  • Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1151754
    Ronnberg E; Ravindran A; Mazzurana L; Gong Y; Safholm J; Lorent J; Dethlefsen O; Orre A-C; Al-Ameri M; Adner M; Dahlen S-E; Dahlin JS; Mjosberg J; Nilsson G
  • Article: CLINICAL AND TRANSLATIONAL ALLERGY. 2023;13(3):e12238
    Björkander S; Klevebro S; Hernandez-Pacheco N; Kere M; Ekström S; Sparreman Mikus M; van Hage M; James A; Kull I; Bergström A; Mjösberg J; Tibbitt CA; Melén E
  • Article: RESPIRATORY RESEARCH. 2023;24(1):62
    Palma Medina LM; Babacic H; Dzidic M; Parke A; Garcia M; Maleki KT; Unge C; Lourda M; Kvedaraite E; Chen P; Muvva JR; Cornillet M; Emgard J; Moll K; Michaelsson J; Flodstrom-Tullberg M; Brighenti S; Buggert M; Mjosberg J; Malmberg K-JK; Sandberg J; Gredmark-Russ S; Rooyackers O; Svensson MJ; Chambers BI; Eriksson L; Pernemalm MK; Bjorkstrom N; Aleman S; Ljunggren H-G; Klingstrom J; Stralin K; Norrby-Teglund A
  • Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;96(1):e13195
    Ljunggren H-G; Heggernes Ask E; Cornillet Jeannin M; Strunz B; Chen P; Rao Muvva J; Akber M; Buggert M; Chambers BJ; Cuapio Gomez A; Dzidic M; Filipovic I; Flodstrom-Tullberg M; Garcia M; Gorin J-B; Gredmark-Russ S; Hertwig L; Klingstrom J; Kokkinou E; Kvedaraite E; Lourda M; Mjosberg J; Maucourant C; Norrby-Teglund A; Palma Medina LM; Parrot T; Perez-Potti A; Ponzetta A; Ringqvist E; Rivera-Ballesteros O; Rooyackers O; Sandberg JK; Sandberg JT; Sekine T; Svensson M; Varnaite R; Wullimann D; Eriksson LI; Aleman S; Malmberg K-J; Stralin K; Bjorkstrom NK
  • Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: GLOBAL. 2022;1(2):37-42
    Mogensen I; Hallberg J; Bjorkander S; Du L; Zuo F; Hammarstrom L; Pan-Hammarstrom Q; Ekstrom S; Georgelis A; Palmberg L; Janson C; Bergstrom A; Melen E; Kull I
  • Visa fler

Alla övriga publikationer

  • Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2024;54:1128
    Boulouis C; Mouchtaridi E; Muller TR; Mak JYW; Fairlie DP; Bergman P; Michaelsson J; Halfvarson J; Mjosberg J; Buggert M; Sandberg JK
  • Editorial comment: CELL RESEARCH. 2024;34(6):403-404
    Spits H; Mjosberg J
  • Preprint: BIORXIV. 2024
    Rødahl IE; Ivarsson MA; Loh L; Mold JE; Westgren M; Friberg D; Mjösberg J; Björkström NK; Marquardt N; Nixon DF; Michaëlsson J
  • Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2023;143(11):S357
    Hoffer E; Zheng W; Beatrice Z; Sortebech D; Agerholm-Nielsen R; Zhang C; Schonfeldt T; Trselic T; Papavasileiou S; Karner J; Ehrstrom M; Gahm J; Mjosberg J; Lysell J; Odum N; Bryceson Y; Brunner P; Gerlach C; Eidsmo L
  • Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2023;62:pa4407
    Kere M; Bjorkander S; Tibbitt CA; Mjosberg J; Melen E
  • Conference publication: EUROPEAN RESPIRATORY JOURNAL. 2023;62:oa2502
    Bjorkander S; Maier P; Kere M; Merid SK; Wirth L; Weigel W; Mjosberg J; Melen E; Tibbitt C
  • Meeting abstract: EUROPEAN RESPIRATORY JOURNAL. 2023;62:oa2495
    Wirth L; Yasinska V; Tibbitt CA; Weigel W; Hochdorfer T; Andersson LI; Sparreman-Mikus M; Dahlen B; Dahlen S-E; Mjosberg J
  • Preprint: BIORXIV. 2023
    Dean I; Lee CYC; Tuong Z; Li Z; Tibbitt C; Willis C; Gaspal F; Kennedy B; Matei-Rascu V; Fiancette R; Nordenvall C; Lindforss U; Baker SM; Stockmann C; Sexl V; Carlesso G; Hammond S; Dovedi S; Mjösberg J; Hepworth M; Clatworthy M; Withers D
  • Review: NATURE REVIEWS IMMUNOLOGY. 2022;22(11):701-712
    Spits H; Mjosberg J
  • Preprint: MEDRXIV. 2022
    García M; García AC; Tauriainen J; Maleki K; Vaheri A; Mäkelä S; Mustonen J; Smed-Sörensen A; Strandin T; Mjösberg J; Klingström J
  • Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;95(4):e13156
    Marchalot A; Mjosberg J
  • Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2021;51:95
    Niessl J; Sekine T; Lange J; Konya V; Forkel M; Maric J; Rao A; Mazzurana L; Kokkinou E; Fehrm J; Sundman J; Price DA; Hodcroft EB; Neher RA; Mjosberg J; Friberg D; Buggert M
  • Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2021;51:155
    Dernstedt A; Leidig J; Holm A; Kerkman PF; Mjosberg J; Ahlm C; Henriksson J; Hultdin M; Forsell MN
  • Editorial comment: ALLERGY. 2021;76(6):1925-1928
    Mjosberg J; Roncarolo MG; Blom B
  • Preprint: MEDRXIV. 2021
    Lourda M; Dzidic M; Hertwig L; Bergsten H; Medina LP; Kvedaraite E; Chen P; Muvva J; Gorin J-B; Cornillet M; Emgård J; Moll K; García M; Maleki K; Klingström J; Michaëlsson J; Flodström-Tullberg M; Brighenti S; Buggert M; Mjösberg J; Malmberg K-J; Sandberg J; Henter J-I; Folkesson E; Gredmark-Russ S; Sönnerborg A; Eriksson L; Rooyackers O; Aleman S; Strålin K; Ljunggren H-G; Björkström N; Svensson M; Ponzetta A; Norrby-Teglund A; Chambers B; the Karolinska KI/K COVID-19 Study Group
  • Preprint: MEDRXIV. 2020
    García M; Kokkinou E; García AC; Parrot T; Palma Medina L; Maleki K; Christ W; Varnaitė R; Filipovic I; Ljunggren H-G; Björkström N; Folkesson E; Rooyackers O; Eriksson L; Sönnerborg A; Aleman S; Strålin K; Gredmark-Russ S; Klingström J; Mjösberg J; the Karolinska KI/K COVID-19 Study Group
  • Review: TRENDS IN IMMUNOLOGY. 2020;41(10):902-917
    Meininger I; Carrasco A; Rao A; Soini T; Kokkinou E; Mjosberg J
  • Preprint: BIORXIV. 2020
    Dernstedt A; Leidig J; Holm A; Mjösberg J; Ahlm C; Henriksson J; Hultdin M; Forsell MN
  • Editorial comment: IMMUNITY. 2020;52(4):573-575
    Kokkinou E; Mjosberg J
  • Conference publication: JOURNAL OF CROHNS & COLITIS. 2020;14:S172
    Garcia AC; Rao A; Kokkinou E; Haapaniemi S; Lindforss U; Winberg ME; Casado-Bedmar M; Fenton T; Jorgensen P; Nordenvall C; Agace W; Keita AV; Soderholm JD; Mjosberg J
  • Visa fler

Forskningsbidrag

  • Swedish Research Council
    1 January 2025 - 31 December 2029
    Biologics targeting type 2 cytokines offer new hope for patients with severe asthma, but not all patients respond, and none are cured. This calls for increased understanding of airway tissue type 2 lymphocytes and how they are regulated by biologics. Innate lymphoid cells type 2 (ILC2) and type 2 T cells (Th2 and Tc2), orchestrate type 2 inflammation. I will build on our unexpected finding that treatment with anti-interleukin (IL)-5 biologics causes an increase in circulating type 2 lymphocytes, implying biologics effects on lymphocyte trafficking, differentiation, and tissue residency. To test this hypothesis, I will capitalize on leading a clinical asthma research unit and immunology lab, enabling us to perform pioneering immunological studies using unique airway tissue samples from patients with severe asthma before and during biologics treatment. My translational team of clinical, immunological and computational researchers will determine the unique features of airway resident lymphocytes and the epigenetic and transcriptional effects of biologics on circulating and airway-resident lymphocytes. We will also dissect the mechanisms involved in lymphocyte trafficking and differentiation in the airways. This will increase the understanding of human airway lymphocyte diversification, trafficking, tissue residency and differentiation in relation to biologics treatment efficacy. Our studies will reveal new targets for treatment and means to better tailor the use of biologics.
  • Swedish Cancer Society
    1 January 2023
    Inflammatory bowel disease (IBD) means an increased risk of developing colorectal cancer, which is thought to be caused by intestinal inflammation giving rise to cell changes and cancer. However, what role the intestinal immune system, mainly lymphocytes such as T cells and innate lymphocytes (ILCs), which I recently discovered in humans, play in this process is unclear. We intend to answer this question by collaborating with clinical researchers where we can perform advanced immunological analyzes of intestinal samples from patients with IBD and colorectal cancer, before and after therapy. We intend to study intestinal lymphocytes with single-cell techniques at both gene expression and protein level, which may reveal new subsets of lymphocytes but also differences between intestinal lymphocytes in the spectrum of healthy-inflamed-tumorous colon. Intestinal lymphocytes will then be analyzed in intestinal samples from IBD patients before and after treatment with new immunomodulatory treatments. Similarly, we will also analyze intestinal samples from patients with colorectal cancer that has spread to the abdominal cavity and are being treated with chemotherapy. Our in-depth analyzes will reveal intestinal lymphocytes that may contribute to inflammation and/or cancer development in the intestine. These studies will also reveal intestinal lymphocytes that may predict or mark response to immunomodulatory therapy in IBD, and chemotherapy in metastatic CRC. This is extremely important because the right choice of effective treatment saves both individual suffering and societal costs.
  • European Research Council
    1 September 2020 - 31 August 2026
    Inflammatory bowel disease (IBD) constitutes an increasing global health burden, yet effective treatments are lacking. Hampering rationale treatment strategies, the human intestinal immune system remains largely unexplored. I have made seminal contributions to the discovery and characterization of innate lymphoid cells (ILCs) (Nat Immunol 2011, 2013 and 2016, Immunity 2012), revealing that in addition to antigen-specific adaptive T cells, innate equivalents play important roles in mucosal immunity. Determining the complementarity and redundancy of these two lymphocyte systems, acting in concert, is important for our understanding of inflammatory diseases and the development of novel therapies. For this proposal, I am in the beneficial position of having access to unique patient samples as well as established methods for single-cell RNA-sequencing to perform an ambitious and comprehensive molecular dissection of the human intestinal lymphocyte compartments in IBD. With this approach, I will determine parallels between known, and identify novel, subsets of tissue-resident, inflammation-associated, innate and adaptive lymphocytes. Building on this unprecedented molecular characterization, we will take on some of the most pressing clinical problems in IBD by performing longitudinal assessments of intestinal lymphocytes from IBD patients on conventional and biological treatments. As only a fraction of patients respond to treatment, this approach provides a golden opportunity to unveil immunological signatures of treatment response and drug-induced transformation of inflammation in non-responders. Furthermore, we will unfold critical disease mechanisms and reveal novel therapy targets and how they can be used to personalize treatment. In summary, my ambitious, yet feasible, proposal combines state-of-the-art technology with access to unique patient materials. My studies are likely to advance our understanding of the complex intestinal lymphocyte network in IBD.
  • Swedish Cancer Society
    1 January 2020
    I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. ILCs are in many ways similar to T cells, whose function can be manipulated by immunotherapy in cancer, so-called check-point blockade. In mice, ILC, like T cells, plays an important role in intestinal inflammation and the development of colon cancer. However, this is unknown in humans. Furthermore, the relationship between ILC and T cells, the way these cells are regulated by the local environment in the tumor, and the way they affect tumor growth in colon cancer are hitherto unknown. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) and their relationship to T cells in colon cancer. My hypothesis is that these cells are regulated by the environment inside the tumor and also have an active role in controlling tumor growth. Through access to unique intestinal tissue samples, I can directly study ILC and T cells that are in the malignant tissue. I can determine in detail their function and thus determine what role these cells can play in colon cancer. My research will increase the understanding of the unique and complementary ways ILCs and T cells act in tumor immunity, and the way in which these cells are regulated by the tumor, but also control tumor growth in colon cancer. The purpose of my research is to find new therapy targets, associated with the interaction between cancer cells and ILC and T cells, that can be used to treat colon cancer.
  • Tissue-specific regulation of human intratumoral innate and adaptive lymphocytes in colorectal cancer
    Swedish Cancer Society
    1 January 2019
    I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. ILCs are in many ways similar to T cells, whose function can be manipulated by immunotherapy in cancer, so-called check-point blockade. In mice, ILC, like T cells, plays an important role in intestinal inflammation and the development of colon cancer. However, this is unknown in humans. Furthermore, the relationship between ILC and T cells, the way these cells are regulated by the local environment in the tumor, and the way they affect tumor growth in colon cancer are hitherto unknown. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) and their relationship to T cells in colon cancer. My hypothesis is that these cells are regulated by the environment inside the tumor and also have an active role in controlling tumor growth. Through access to unique intestinal tissue samples, I can directly study ILC and T cells that are in the malignant tissue. I can determine in detail their function and thus determine what role these cells can play in colon cancer. My research will increase the understanding of the unique and complementary ways ILCs and T cells act in tumor immunity, and the way in which these cells are regulated by the tumor, but also control tumor growth in colon cancer. The purpose of my research is to find new therapy targets, associated with the interaction between cancer cells and ILC and T cells, that can be used to treat colon cancer.
  • Swedish Research Council
    1 January 2019 - 31 December 2024
  • Swedish Research Council
    1 January 2019
    Inflammatory bowel disease (IBD) constitutes an increasing global health burden. Hampering rationale treatment strategies, the human intestinal immune system remains largely unexplored. I have made seminal discoveries of innate lymphoid cells (ILC) (Nat Immunol 2011, 2013 and 2016, Immunity 2012), revealing that in addition to adaptive T cells, their innate equivalents, ILC, contribute to mucosal immunity. I am in the beneficial position of having access to unique patient samples as well as established methods for single-cell RNA-sequencing and epigenetic investigations (ATAC-seq) to perform a comprehensive molecular dissection of the human intestinal lymphocyte compartments in IBD. With this approach, we will determine functional and spatial parallels between known, and identify novel, subsets of tissue-resident, inflammation-associated, innate and adaptive lymphocytes (year 1-3). Building on this unprecedented molecular characterization, we will perform longitudinal assessments of intestinal lymphocytes from treated IBD patients (year 4-5). This approach provides a golden opportunity to unveil immunological signatures of treatment response, disease mechanisms and novel therapy targets. In summary, my ambitious, yet feasible, proposal combines state-of-the-art technology with access to unique patient materials. My established team will work closely together with clinicians and other scientists to advance our understanding of the complex intestinal lymphocyte network in IBD.
  • Importance of the lymphoid cells of the innate immune system in inflammatory bowel disease and colon cancer
    Swedish Cancer Society
    1 January 2018
    Prolonged inflammatory bowel disease (IBD) represents a dramatically increased risk of colon cancer. It is likely that the chronic inflammation of IBD is a direct cause of colon cancer and therefore IBD can be seen as a precursor to cancer. I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. In mice, these cells have a very important role in intestinal inflammation and tumor development, but the specific link between the role of ILC in IBD and colon cancer in humans has not yet been investigated. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) in inflammatory bowel disease (IBD) and colon cancer. My hypothesis is that these cells are directly involved in the development of IBD and thereby colon cancer and also have an active role in regulating cancer growth. By accessing unique intestinal tissue samples, I can directly study the ILC contained in the inflamed or malignant tissue. I can in detail determine their function and thus determine what role these cells can play in IBD and colon cancer. My hypothesis is that congenital lymphoid cells (ILC) are extremely important actors in inflammatory bowel disease (IBD) and colon cancer. My research will increase understanding of this group of cells in general, and especially their role in IBD and colon cancer. IBD can be seen as a precursor to cancer. Thus, knowledge of IBD is extremely important in preventing the onset of colon cancer. The purpose of my research is to find new therapy goals associated with ILC, which can be used for prevention and treatment of IBD and colon cancer.
  • Importance of the lymphoid cells of the innate immune system in inflammatory bowel disease and colon cancer
    Swedish Cancer Society
    1 January 2017
    Prolonged inflammatory bowel disease (IBD) represents a dramatically increased risk of colon cancer. It is likely that the chronic inflammation of IBD is a direct cause of colon cancer and therefore IBD can be seen as a precursor to cancer. I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. In mice, these cells have a very important role in intestinal inflammation and tumor development, but the specific link between the role of ILC in IBD and colon cancer in humans has not yet been investigated. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) in inflammatory bowel disease (IBD) and colon cancer. My hypothesis is that these cells are directly involved in the development of IBD and thereby colon cancer and also have an active role in regulating cancer growth. By accessing unique intestinal tissue samples, I can directly study the ILC contained in the inflamed or malignant tissue. I can in detail determine their function and thus determine what role these cells can play in IBD and colon cancer. My hypothesis is that congenital lymphoid cells (ILC) are extremely important actors in inflammatory bowel disease (IBD) and colon cancer. My research will increase understanding of this group of cells in general, and especially their role in IBD and colon cancer. IBD can be seen as a precursor to cancer. Thus, knowledge of IBD is extremely important in preventing the onset of colon cancer. The purpose of my research is to find new therapy goals associated with ILC, which can be used for prevention and treatment of IBD and colon cancer.
  • Importance of the lymphoid cells of the innate immune system in inflammatory bowel disease and colon cancer
    Swedish Cancer Society
    1 January 2016
    Prolonged inflammatory bowel disease (IBD) represents a dramatically increased risk of colon cancer. It is likely that the chronic inflammation of IBD is a direct cause of colon cancer and therefore IBD can be seen as a precursor to cancer. I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. In mice, these cells have a very important role in intestinal inflammation and tumor development, but the specific link between the role of ILC in IBD and colon cancer in humans has not yet been investigated. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) in inflammatory bowel disease (IBD) and colon cancer. My hypothesis is that these cells are directly involved in the development of IBD and thereby colon cancer and also have an active role in regulating cancer growth. By accessing unique intestinal tissue samples, I can directly study the ILC contained in the inflamed or malignant tissue. I can in detail determine their function and thus determine what role these cells can play in IBD and colon cancer. My hypothesis is that congenital lymphoid cells (ILC) are extremely important actors in inflammatory bowel disease (IBD) and colon cancer. My research will increase understanding of this group of cells in general, and especially their role in IBD and colon cancer. IBD can be seen as a precursor to cancer. Thus, knowledge of IBD is extremely important in preventing the onset of colon cancer. The purpose of my research is to find new therapy goals associated with ILC, which can be used for prevention and treatment of IBD and colon cancer.
  • Deutsche Forschungsgemeinschaft
    1 January 2016 - 31 December 2019
  • Importance of the lymphoid cells of the innate immune system in inflammatory bowel disease and colon cancer
    Swedish Cancer Society
    1 January 2015
    Prolonged inflammatory bowel disease (IBD) represents a dramatically increased risk of colon cancer. It is likely that the chronic inflammation of IBD is a direct cause of colon cancer and therefore IBD can be seen as a precursor to cancer. I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. In mice, these cells have a very important role in intestinal inflammation and tumor development, but the specific link between the role of ILC in IBD and colon cancer in humans has not yet been investigated. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) in inflammatory bowel disease (IBD) and colon cancer. My hypothesis is that these cells are directly involved in the development of IBD and thereby colon cancer and also have an active role in regulating cancer growth. By accessing unique intestinal tissue samples, I can directly study the ILC contained in the inflamed or malignant tissue. I can in detail determine their function and thus determine what role these cells can play in IBD and colon cancer. My hypothesis is that congenital lymphoid cells (ILC) are extremely important actors in inflammatory bowel disease (IBD) and colon cancer. My research will increase understanding of this group of cells in general, and especially their role in IBD and colon cancer. IBD can be seen as a precursor to cancer. Thus, knowledge of IBD is extremely important in preventing the onset of colon cancer. The purpose of my research is to find new therapy goals associated with ILC, which can be used for prevention and treatment of IBD and colon cancer.
  • Importance of the lymphoid cells of the innate immune system in inflammatory bowel disease and colon cancer
    Swedish Cancer Society
    1 January 2014
    Prolonged inflammatory bowel disease (IBD) represents a dramatically increased risk of colon cancer. It is likely that the chronic inflammation of IBD is a direct cause of colon cancer and therefore IBD can be seen as a precursor to cancer. I, along with several other research groups, have recently discovered a new cell family in the immune system. These are called "congenital lymphoid cells" (ILC) and are found in both mice and humans. In mice, these cells have a very important role in intestinal inflammation and tumor development, but the specific link between the role of ILC in IBD and colon cancer in humans has not yet been investigated. The purpose of my project is to investigate the role of congenital lymphoid cells (ILC) in inflammatory bowel disease (IBD) and colon cancer. My hypothesis is that these cells are directly involved in the development of IBD and thereby colon cancer and also have an active role in regulating cancer growth. By accessing unique intestinal tissue samples, I can directly study the ILC contained in the inflamed or malignant tissue. I can in detail determine their function and thus determine what role these cells can play in IBD and colon cancer. My hypothesis is that congenital lymphoid cells (ILC) are extremely important actors in inflammatory bowel disease (IBD) and colon cancer. My research will increase understanding of this group of cells in general, and especially their role in IBD and colon cancer. IBD can be seen as a precursor to cancer. Thus, knowledge of IBD is extremely important in preventing the onset of colon cancer. The purpose of my research is to find new therapy goals associated with ILC, which can be used for prevention and treatment of IBD and colon cancer.
  • Swedish Research Council
    1 January 2014 - 31 December 2018
  • Innate lymphoid cells in gut inflammation and cancer
    Swedish Foundation for Strategic Research
    1 September 2013 - 31 December 2016
  • Swedish Research Council
    16 July 2012 - 31 May 2013
  • FWF Austrian Science Fund
    1 March 2012 - 30 June 2021
  • Recently discovered the role of congenital lymphoida cells in human inflammatory bowel disease
    Swedish Research Council
    1 January 2011 - 30 September 2012

´¡²Ô²õ³Ùä±ô±ô²Ô¾±²Ô²µ²¹°ù

  • Professor, Medicin, Huddinge, ̽»¨¾«Ñ¡, 2022-

Examina och utbildning

  • Docent, Immunologi, ̽»¨¾«Ñ¡, 2019

Handledning

  • Handledning till doktorsexamen

    • Malin Ljunggren, Metastatic colorectal cancer - identifying the patients that receive and benefit from treatment with curative intent, /en/people/malin-ljunggren, 2021-

Nyheter från KI

Kalenderhändelser från KI